Michael Benkowitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

United Therapeutics Corporation beats earnings expectations. Reported EPS is $6.17, expectations were $5.65.

United Therapeutics impresses with record-breaking Q1 results. Revenue soars 34% Y/Y to $677.7 million, EPS jumps to $6.17. Tyvaso leads the charge with a 56% revenue surge.

On Wednesday, United Therapeutics Corporation (NASDAQ:UTHR) reported first-quarter sales of $677.7 million, up 34% year over year, beating the consensus of $623.9 million. The company reported EPS of $6.17, up from $4.86 a year ago, surpassing the consensus of $5.56. “The first quarter of 2024 represents another quarter of record revenue and double-digit year-over-year revenue growth,” jointly said Martine Rothblatt, Chairperson and Chief Executive Officer and Michael Benkowitz, President and Ch

United Therapeutics Corporation , a public benefit corporation, announced today that Michael Benkowitz, President and Chief Operating Officer, will provide an overview and update on the company’s...

United Therapeutics Corporation (NASDAQ:UTHR) Q4 2023 Earnings Call Transcript February 21, 2024 United Therapeutics Corporation beats earnings expectations. Reported EPS is $4.36, expectations were $3.92. United Therapeutics Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]